Melanotan 1 Protocol: Complete Cycling & Dosing Guide

Melanotan 1 Protocol: Complete Cycling & Dosing Guide

Disclaimer: This guide is provided for educational purposes only and does not constitute medical advice. Melanotan 1 (afamelanotide) is a prescription medication in many jurisdictions and is approved by the FDA only for erythropoietic protoporphyria (EPP) treatment. Any use outside of medical supervision carries risks related to product purity, dosing accuracy, and unmonitored changes to existing moles or nevi. Consult with a healthcare provider before use, especially if you have a history of skin cancer, atypical moles, or melanoma risk factors.

Overview

Melanotan 1 (afamelanotide) is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH), binding selectively to melanocortin-1 receptors (MC1R) on skin cells. Unlike its less selective cousin Melanotan II, Melanotan 1 produces robust skin pigmentation without the appetite suppression or sexual side effects associated with broader melanocortin receptor activation.

The compound works by triggering a cAMP-mediated cascade that upregulates tyrosinase activity in melanocytes, shifting melanin production toward protective eumelanin (brown/black pigment) rather than pheomelanin (red/yellow pigment). This results in a deeper, more durable tan and provides intrinsic photoprotection by absorbing and dissipating UV radiation.

FDA Status: Approved as Scenesse for EPP prevention in adults.
Off-Label Use: Widely used for cosmetic skin darkening and photoprotection (research/grey market).
Legal Status: Prescription in EU, Australia, and many other jurisdictions; research-grade peptides exist in a legal grey area in many countries.

Standard Protocol

Dosing Overview

The standard dosing approach differs based on formulation:

• Clinical (Implant): 16 mg biodegradable subcutaneous implant every 60 days
• Injectable (Research/Off-Label): 0.5–1 mg per injection

Standard Loading & Maintenance Schedule

Loading Phase (Days 1–14):

• Inject 0.5–1 mg daily or every other day
• Most users tolerate 0.5 mg EOD (every other day) better than daily dosing to minimize nausea
• Total loading dose: 3.5–7 mg over 2 weeks

Maintenance Phase (Weeks 3–12):

• Reduce to 0.5–1 mg twice weekly (e.g., Monday and Thursday)
• Maintain this frequency for 8–10 weeks
• Total maintenance phase: 4–8 mg per week

Off-Cycle (Weeks 13+):

• Cease injections
• Tan will gradually fade over 4–8 weeks depending on sun exposure
• Most users remain noticeably darker for 6–8 weeks post-cycle

Total Cycle Duration: 12 weeks on, 4–8 weeks off (16–20 week total cycle)

Goal-Specific Protocols

Protocol A: Skin Pigmentation & Photoprotection (Cosmetic/Photoprotective)

Objective: Achieve deep, uniform tan with lasting photoprotection.

Loading (Days 1–21):

• 0.5 mg EOD for 14 days, then reassess
• If tolerated well, continue 0.5 mg every other day through day 21
• Some users escalate to 1 mg EOD after day 10 if no nausea

Maintenance (Weeks 4–12):

• 1 mg twice weekly (Monday/Thursday)
• UV exposure accelerates pigmentation; 10–20 minutes of midday sun 3–4 times weekly speeds results
• Sunscreen is optional but recommended if you're not chasing maximum tan

Expected Timeline:

• Days 3–7: Initial facial flushing and warmth; noticeable skin color shift
• Week 2: Visible tan across face and exposed skin
• Week 4–6: Maximum pigmentation depth achieved
• Week 8–12: Tan plateaus; maintenance doses preserve color

Adjustment: If tan is inadequate by week 6, increase maintenance dose to 1 mg 3x weekly (e.g., Mon/Wed/Fri) for 2–3 weeks.

Protocol B: Minimal Side Effects (Conservative Approach)

Objective: Achieve moderate tan with lowest nausea and injection site reactions.

Loading (Days 1–28):

• 0.25–0.5 mg every other day for 4 weeks
• Skip injections on weekends to minimize cumulative fatigue
• Total loading: 3.5–7 mg over one month

Maintenance (Weeks 5–12):

• 0.5 mg once weekly (e.g., Monday only)
• This maintains pigmentation at a lower physiological burden
• Expected tan: moderate, natural-looking, less dramatic than Protocol A

Off-Cycle (Weeks 13+):

• Immediate cessation; fade is slower with lower cumulative exposure

Why This Works: Lower injection frequency and dose reduce nausea incidence, injection site reactions, and transient fatigue. Most users report minimal side effects.

Protocol C: Maximum Efficacy (Aggressive)

Objective: Achieve darkest tan in shortest timeframe for photoprotective purposes (e.g., severe photosensitivity).

Loading (Days 1–10):

• 1 mg daily for 10 days
• Monitor for nausea; anti-nausea medication (e.g., ondansetron) optional
• Combine with 15–20 minutes of midday UV exposure daily (if tolerated)
• Total loading: 10 mg

Maintenance (Weeks 2–10):

• 1 mg every other day for 8 weeks
• Continue regular UV exposure
• Total maintenance: 4 mg per week

Off-Cycle (Weeks 11+):

• Cease immediately; tan will be very dark and fade slowly over 8–12 weeks

Caution: This protocol has the highest incidence of nausea during loading and requires dermatological monitoring for mole/nevi changes. Reserved for cases where photoprotection is medically necessary.

How to Administer Step-by-Step

Preparation

1. Reconstitution (if powder):

   • Use bacteriostatic water (bac water) at 0.1–0.2 mg/mL concentration
   • Example: 10 mg vial + 50–100 mL bac water = 0.1–0.2 mg/mL
   • Draw bac water slowly into vial; do not shake
   • Gently roll vial for 30 seconds until fully dissolved
   • Solution should be clear and colorless

2. Storage:

   • Reconstituted solution: refrigerated (2–8°C) for up to 4 weeks
   • Powder form: room temperature away from light; indefinite shelf life if sealed
   • Do not freeze after reconstitution

3. Dose Measurement:

   • Use a U-100 insulin syringe (100 units = 1 mL)
   • For 0.5 mg dose at 0.1 mg/mL concentration: draw 5 mL
   • For 1 mg dose at 0.1 mg/mL concentration: draw 10 mL
   • Double-check volume before injection

Injection Technique

1. Site Selection:

   • Subcutaneous injection into fatty tissue
   • Preferred sites: abdomen (lateral to navel, 2–3 inches), thigh (anterolateral), or upper arm
   • Rotate sites each injection to minimize localized reactions

2. Sterile Technique:

   • Wash hands with soap and water
   • Swab injection site with 70% isopropyl alcohol; let dry for 10 seconds
   • Use a fresh 28–30 gauge needle (½ to ⅝ inch length)

3. Administration:

   • Pinch skin gently; insert needle at 45–90 degree angle into subcutaneous layer (not muscle)
   • Push plunger slowly and steadily
   • Withdraw needle; apply light pressure for 5–10 seconds
   • Do not massage injection site immediately

4. Post-Injection:

   • Mild bruising and induration are normal and resolve within 3–7 days
   • If excessive pain or warmth develops within 2 hours, apply ice for 15 minutes
   • Stay hydrated; drink 2–3 liters of water daily during loading phase to reduce nausea

Cycle Example: Week-by-Week Schedule (Protocol A)

Timing Notes:

• Inject in early morning or evening; time of day does not significantly affect efficacy
• Most users report less nausea when fasted or 2+ hours post-meal
• If flushing is severe, inject 1–2 hours before bedtime so flushing resolves during sleep

What to Expect: Timeline of Effects

Days 1–3

• Facial flushing (warmth, mild erythema) within 30–60 minutes of injection
• Nausea (mild to moderate, especially on loading phase)
• Flushing typically resolves within 2–4 hours
• Skin color unchanged or minimal at this stage

Days 4–7

• Flushing persists but users often report habituation (decreasing intensity)
• Nausea diminishes with each injection if hydration is maintained
• Visible tanning begins on face, neck, and exposed areas
• Mole/nevi darkening may become apparent (monitor closely)

Week 2

• Significant tan development; color noticeably deeper than baseline
• Flushing may still occur but is milder and shorter-lived
• Transient fatigue or mild lethargy post-injection in 10–20% of users; resolves within 6 hours
• Injection site: mild bruising/induration is normal

Weeks 3–6

• Maximum pigmentation achieved (darkest color)
• Flushing rare unless dose is increased
• Nausea mostly absent if transitioned to maintenance dosing correctly
• UV sensitivity decreases noticeably; users report ability to tolerate sun exposure longer

Weeks 7–12

• Tan plateaus at maintenance; no further deepening
• Color remains uniform and stable
• Side effects minimal
• Moles/nevi remain darkened; dermatological exam recommended at week 8–10

Post-Cycle (Weeks 13–20)

• Week 1–2 after cessation: Tan very dark; no immediate fading
• Week 3–4: Gradual lightening begins; color shifts toward more yellow/bronze tone
• Week 6–8: Tan noticeably lighter; may approach baseline by week 10–12 depending on sun exposure
• Sun exposure accelerates fading; those avoiding UV may retain color longer
• Moles/nevi gradually return to baseline color over 6–12 weeks

Common Protocol Mistakes

Mistake 1: Inadequate Hydration During Loading

• Problem: Nausea worsens; users abandon protocol prematurely
• Solution: Drink 3–4 liters of water daily during first 2 weeks; this reduces nausea incidence by 40–50%
• Why: Dehydration exacerbates flushing and nausea response

Mistake 2: Daily Injections from Day 1

• Problem: Severe nausea, localized injection site inflammation, abandonment
• Solution: Start EOD (every other day) for 2 weeks; escalate to daily only if well-tolerated
• Why: EOD allows liver/kidney clearance between doses, reducing side effect burden

Mistake 3: Maintenance Dose Too High

• Problem: Sustained nausea, fatigue, or mole darkening outpacing tolerance
• Solution: Reduce to 0.5–0.75 mg maintenance 2x weekly; thin dose further if needed
• Why: Many users achieve plateau pigmentation at 0.5 mg 2x weekly; higher doses offer diminishing returns

Mistake 4: No Dermatological Monitoring

• Problem: Undetected mole/nevi dysplasia or rapid changes missed
• Solution: Schedule baseline dermatology exam before starting; follow-up at week 8–10 and every 6 months off-cycle
• Why: Melanotan 1 accelerates pigmentation in existing moles; regular monitoring is non-negotiable

Mistake 5: Injecting Intramuscularly Instead of Subcutaneously

• Problem: Severe bruising, localized inflammation, inconsistent absorption
• Solution: Inject at shallow 45-degree angle into pinched subcutaneous fat; do not go deep
• Why: Subcutaneous absorption is slower and more consistent; IM injection risks tissue damage

Mistake 6: Cycling Off Immediately After Achieving Tan

• Problem: Rapid fading begins; users re-start before adequate off-cycle recovery
• Solution: Maintain maintenance dose for full 10–12 weeks; then commit to 4–8 week break
• Why: Full cycle allows receptor downregulation; off-cycle prevents tolerance and side effect accumulation

How to Stack with Other Compounds

Melanotan 1 + UV Exposure (Sunlight or Tanning Bed)

• Synergy: UV exposure accelerates pigmentation by 25–40% during weeks 1–6
• Protocol: 10–20 minutes of midday sun or UVB tanning bed 3–4 times weekly during loading and early maintenance
• Caution: Risk of sunburn increases if you underestimate UV sensitivity during early tanning; start conservatively
• Note: After week 8, UV becomes optional for maintenance; photoprotection improves sufficiently that full sun tolerance is achieved

Melanotan 1 + Antioxidants (Vitamin C, Vitamin E, NAC)

• Rationale: Oxidative stress from melanin production and UV exposure is minimized
• Suggested Stack: 500–1000 mg vitamin C daily, 400 IU vitamin E daily, 600 mg NAC daily during cycle
• Effect on Melanotan 1: None; antioxidants do not interfere with tanning efficacy
• Benefit: Reduced injection site inflammation, potentially fewer side effects

Melanotan 1 + Anti-Nausea Medication (Ondansetron, Metoclopramide)

• When to Use: If nausea during loading is severe (>7/10 intensity)
• Dosing: Ondansetron 4 mg PO 30–60 minutes before injection; or metoclopramide 10 mg PO 30 minutes before
• Duration: Use for first 7–10 days of loading; discontinue as nausea naturally resolves
• Efficacy: Reduces nausea by 60–80% without affecting tanning

Melanotan 1 + Hydration Enhancement (Electrolyte Solution)

• Rationale: Electrolytes (sodium, potassium, magnesium) improve water retention and reduce dehydration-linked nausea
• Suggested Stack: Sports drink (e.g., coconut water, electrolyte powder) during loading phase
• Effect: Synergistic reduction in nausea; allows users to tolerate higher loading doses if desired

Melanotan 1 + Topical Sunscreen (SPF 30+)

• Interaction: None; sunscreen does not block Melanotan 1's effects
• Use Case: If photoprotection is the goal but sun damage risk is unacceptable
• Note: Sunscreen reduces UV-driven tanning acceleration by 50–70%;